TRIPLETE: Phase III Trial of First-line mFOLFOXIRI + Panitumumab vs mFOLFOX6 + Panitumumab in RAS/BRAF Wild-Type mCRC

June 3-7, 2022; Chicago, Illinois
Intensification of first-line chemotherapy with mFOLFOXIRI in combination with panitumumab did not improve response rate, depth of response, or PFS in patients with RAS and BRAF wild-type mCRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 173 KB
Released: June 9, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.

Related Content

From ASCO GI 2023, preliminary safety and efficacy data from the LEAP-015 study of pembrolizumab + lenvatinib + CT for gastroesophageal cancer, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

Data from ASCO GI 2023 from the SPOTLIGHT trial of zolbetuximab + mFOLFOX6 for CLDN18.2-positive/HER2-negative gastric cancers, as reported by Clinical Care Options (CCO)

Released: January 25, 2023

Experts highlight key studies being presented at the upcoming 2023 ASCO GI annual meeting in this commentary from Clinical Care Options (CCO)

Christopher H. Lieu, MD Rachna Shroff, MD, MS Released: January 19, 2023

In slides from Clinical Care Options (CCO), experts provide perspectives on updates in biomarker testing and targeted therapy across GI cancers

John L. Marshall, MD
Program Director
Christopher H. Lieu, MD Manish A. Shah, MD
Released: January 19, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings